Shannon Smith, MD
Urology · Fairbanks, AKNPI 1043673791
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Boston Scientific at 54.4% of the total. Reporting peaked in 2024 at $2,362 and has fallen 64.2% since, to $846 in 2025.
Across 18 payments — averaging $184.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Teleflex LLC$668
- Uromedica, Incorporated$555
- Organogenesis Inc.$112
- Coloplast$110
- Innovation Technologies Inc$37
- plus $32 from 1 others
What the payments were for
- Travel & lodging$1,83755%
- Food & beverage$92828%
- Education$55517%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $1,807 |
| Teleflex LLC | 2 | $668 |
| Uromedica, Incorporated | 1 | $555 |
| Organogenesis Inc. | 1 | $112 |
| Coloplast | 1 | $110 |
| Innovation Technologies Inc | 1 | $37 |
| Calyxo, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,320 in reported general payments places this provider in the 60th percentile of 28 urology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 47 | $27,174 |
| GemtesaVibegron | 28 | $13,282 |
| Estradiol | 49 | $3,017 |
| Pentoxifylline | 18 | $538 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $449 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $353 |
| Tamsulosin Hcl | 32 | $319 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $83 |
| Cephalexin | 15 | $81 |
| Levofloxacin | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other urology in Fairbanks
- David SharpFairbanks$6K
- Tony NimehFairbanks$4K
- Max LevittFairbanks$4K
- Joshua LoganAnchorage$16K
- William ClarkAnchorage$9K
- Elysia SpencerAnchorage$8K
- Andre GodetAnchorage$5K
- Bryan WilsonAnchorage$4K
- Doug ChoJber$4K
- Mariam MillerAnchorage$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.